- Home
- SWKS vs JAZZ Comparison
SWKS vs JAZZ Comparison
Compare SWKS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWKS | JAZZ |
|---|---|---|
| Founded | 1962 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 10.4B |
| IPO Year | 1995 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SWKS | JAZZ |
|---|---|---|
| Price | $53.59 | $189.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $72.85 | ★ $216.92 |
| AVG Volume (30 Days) | ★ 2.6M | 677.9K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $4,086,900,000.00 | $1,618,693,000.00 |
| Revenue This Year | N/A | $6.17 |
| Revenue Next Year | $3.01 | $7.66 |
| P/E Ratio | $99.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $47.93 | $95.49 |
| 52 Week High | $90.90 | $198.00 |
Technical Indicators
Market Signals| Indicator | SWKS | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 39.83 | 59.96 |
| Support Level | $52.95 | $159.78 |
| Resistance Level | $56.44 | $198.00 |
| Average True Range (ATR) | 1.89 | 4.73 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 30.16 | 83.65 |
Price Performance
Historical ComparisonAbout SWKS Skyworks Solutions Inc.
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.